全國服務咨詢熱線：
13761418683
13761418683
簡要描述：BIBF 1120 esylate 656247-18-6 BIBF 1120 esylate是一種有效的 VEGFR1/2/3，F(xiàn)GFR1/2/3 和 PDGFRα/β 三重抑制劑，IC50 值分別為 34 nM/13 nM/13 nM，69 nM/37 nM/108 nM 和 59 nM/65 nM。
產(chǎn)品型號：abs812859廠商性質(zhì)：生產(chǎn)廠家更新時間：2026-02-26訪 問 量：2524產(chǎn)品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 656247-18-6 |
|---|---|---|---|
| 分子式 | C31H33N5O4.C2H6O3S | 純度 | ≥98% |
| 分子量 | 649.76 | 貨號 | abs812859 |
| 規(guī)格 | 10mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | 是一種有效的 VEGFR1/2/3,FGFR1/2/3 和 PDGFRα/β 三 | 應用領域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
BIBF 1120 esylate 656247-18-6
| 產(chǎn)品描述 | |
| 描述 | BIBF 1120 esylate是一種有效的 VEGFR1/2/3，F(xiàn)GFR1/2/3 和 PDGFRα/β 三重抑制劑，IC50 值分別為 34 nM/13 nM/13 nM，69 nM/37 nM/108 nM 和 59 nM/65 nM。 |
| 純度 | ≥98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | Nintedanib esylate |
| 可溶性/溶解性 | DMSO: 92.85 mg/mL |
| 生物活性 | |
| 靶點 | FGFR |
| In vitro(體外研究) | BIBF 1120 binds to the ATP-binding site in the cleft between the amino and carboxy terminal lobes of the kinase domain. BIBF 1120 inhibits proliferation of PDGF-BB stimulated BRPs with EC50 of 79 nM in cell assays. BIBF1120 (100 nM) blocks activation of MAPK after stimulation with 5% serum plus PDGF-BB. BIBF1120 prevents PDGF-BB stimulated proliferation with an EC50 of 69 nM in cultures of human vascular smooth muscle cells (HUASMC). |
| In vivo(體內(nèi)研究) | BIBF1120 (25-100 mg/kg daily p.o.) is highly active in all tumor models, including human tumor xenografts growing in nude mice and a syngeneic rat tumor model. This is evident in the magnetic resonance imaging of tumor perfusion after 3 days, reducing vessel density and vessel integrity after 5 days, and profound growth inhibition. BIBF1120 is orally available and displays encouraging efficacy in in vivo tumor models while being well tolerated. |
| 參考文獻 | |
| 參考文獻 | [1]. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68(12), 4774-4782. [2]. Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem, 2009, 52(14), 4466-4480. [3]. Suzuki N, et al. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep. 2016 Dec;36(6):3123-3130. |
| 研究領域 | |
| 研究領域 | CancerCancer MetabolismResponse to hypoxia CancerOncoproteins/suppressorsOncoproteinsGrowth factor receptors CardiovascularAngiogenesisEndothelial Cell Markers CardiovascularCardiovascular MarkersCell MarkersEndothelial Cells MetabolismTypes of diseaseCancer MetabolismPathways and ProcessesMetabolism processesHypoxia MicrobiologyInterspecies InteractionHost Virus Interaction NeuroscienceDevelopment NeuroscienceProcesses Signal TransductionProtein PhosphorylationTyrosine KinasesReceptor Tyrosine Kinases Stem CellsEndothelial ProgenitorsEndothelial Markers Stem CellsHematopoietic ProgenitorsSurface Molecules Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：zhouzz@univ-bio.com
傳真：